Lexicon Pharmaceutical ( Lexicon Pharmaceutical )

Lexicon Pharmaceutical

Lexicon Pharmaceutical's picture

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering and developing breakthrough treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Arthur T Sands, Ray B Webb and. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets.

Lexicon Pharmaceutical press release, blog etc

03/28/2018 - 23:37 Lexicon Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application (MAA) for Sotagliflozin to Treat Adults with Type 1 Diabetes
03/26/2018 - 04:55 Lexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults with Type 1 Diabetes
02/28/2018 - 05:56 Lexicon Pharmaceuticals Announces Poster Presentation at the 15th Annual ENETS Conference
01/02/2018 - 15:44 Lexicon Pharmaceuticals Announces Poster Presentation at ASCO GI
01/02/2018 - 06:59 Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
12/05/2017 - 17:15 Lexicon Pharmaceuticals Secures Up To $200 Million Non-dilutive Term Loan Financing
09/27/2017 - 04:24 Lexicon Pharmaceuticals Initiates Patient Dosing in a Phase 1 Study of LX9211
09/19/2017 - 14:19 European Commission Approves Xermelo (Telotristat ethyl) for the Treatment of Carcinoid Syndrome Diarrhea in Combination with Somatostatin Analog Therapy
09/18/2017 - 06:05 Lexicon Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
09/13/2017 - 04:10 New England Journal of Medicine Publishes Data from Phase 3 inTandem3 Study of Sotagliflozin in Patients with Type 1 Diabetes
09/08/2017 - 09:02 Lexicon Pharmaceuticals Reports Positive Pooled Continuous Glucose Monitoring Data from Pivotal Phase 3 Intandem1 and inTandem2 Studies of Sotagliflozin
09/07/2017 - 04:02 Lexicon Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Global Healthcare Conference
09/07/2017 - 03:08 Lexicon Pharmaceuticals Announces Four Data Presentations at the European Society of Medical Oncology 2017 Congress
09/05/2017 - 08:35 Lexicon Pharmaceuticals to Present New Clinical Data at the European Association for the Study of Diabetes 53rd Annual Meeting
08/15/2017 - 07:32 Lexicon Pharmaceuticals Reports Additional Positive Data from Pivotal Phase 3 Intandem2 Study of Sotagliflozin
08/03/2017 - 08:07 Lexicon Pharmaceuticals to Present at 2017 Wedbush Pacgrow Healthcare Conference
07/31/2017 - 05:12 Lexicon Pharmaceuticals Announces Opt-in Decision for U.S. Co-Promotion of Sotagliflozin with Sanofi in Type 1 Diabetes
07/21/2017 - 07:10 Lexicon Collaborator Ipsen Receives Positive CHMP Opinion for XERMELO (Telotristat Ethyl)